LEADS BIOLABS-B(09887): One LBL-034 clinical study has been selected to be the first oral presentation on the first day of the 67th ASH Annual Meeting.

LEADS BIOLABS-B(09887) has announced that 5 research abstracts have been selected to be presented at the 67th annual meeting of the American Society of Hematology. The company is pleased to provide further details on its investigational new drugs LBL-034 and LBL-076, with multiple research abstracts on these drugs being included in the 67th ASH Annual Meeting. One clinical study on LBL-034 has been selected to be the first oral presentation on the opening day of the conference, showcasing the latest efficacy and safety data of LBL-034 in relapsed/refractory multiple myeloma patients.